Ipsen's Elafibranor Demonstrates Sustained Efficacy in Primary Biliary Cholangitis Phase III Trial
核心洞察
Ipsen's elafibranor achieved a 70% biochemical response rate at 78 weeks in the ELATIVE Phase III trial for primary biliary cholangitis (搜索), compared to 0% with placebo.
The novel PPAR (搜索) agonist demonstrated significant improvements in itch-related quality of life, with 58% of patients reporting reduced itching duration and 80% experiencing improved sleep disturbance.
Elafibranor is currently under regulatory review by the FDA, EMA, and UK MHRA as a potential first-in-class treatment for patients with inadequate response to standard therapy.
Ipsen announced compelling long-term efficacy data for elafibranor in primary biliary cholangitis (搜索) (PBC) at the European Association for the Study of the Liver (EASL) Congress, demonstrating sustained disease control and symptom improvement after 78 weeks of treatment. The Phase III ELATIVE trial results show 70% of patients treated with elafibranor achieved the composite endpoint of biochemical response, compared to 0% receiving placebo.
Sustained Biochemical Response at 78 Weeks
The ELATIVE Phase III trial evaluated 43 patients who completed their week-78 double-blind visit, with 30 receiving elafibranor and 13 receiving placebo. The composite endpoint required alkaline phosphatase (ALP) levels below 1.67 times the upper limit of normal, an ALP decrease of at least 15%, and total bilirubin within normal limits. These biomarkers serve as important predictors of PBC disease progression, with reductions indicating reduced liver injury and improved function.
"There are a significant proportion of people living with PBC who experience worsening disease and debilitating symptoms despite being on treatment," said Sandra Silvestri, M.D., Executive Vice President and Chief Medical Officer at Ipsen. "These long-term data from the Phase III ELATIVE study further demonstrate the potential for elafibranor to provide an effective treatment option for these patients."
Quality of Life Improvements
Beyond biochemical markers, elafibranor demonstrated meaningful improvements in patient-reported outcomes related to pruritus, one of the most debilitating symptoms of PBC. At week 52, treatment with elafibranor led to greater reductions in 5-D Itch scores across five domains: degree, duration, dimension, disability, and distribution.
Specifically, 58% of patients receiving elafibranor reported reduced itching duration at week 52, compared with 27% on placebo. Sleep disturbance, a common consequence of severe itching, improved dramatically with 80% of elafibranor-treated patients experiencing no sleep disturbance or only occasional delay, versus 30% on placebo.
Clinical Significance and Regulatory Status
Dr. Christopher Bowlus, Professor of Gastroenterology and Hepatology at University of California Davis, emphasized the clinical importance of these findings: "When you have a patient with PBC, it's vital to manage disease progression, to prevent or delay liver damage or failure. You also want to provide relief from distressing symptoms because they can have a very detrimental impact on quality of life."
Elafibranor represents a novel, potential first-in-class PPAR (搜索) agonist currently under review by the U.S. Food and Drug Administration, the European Medicines Agency, and the UK Medicines and Healthcare Products Regulatory Authority. The drug addresses a significant unmet need in PBC treatment, particularly for patients with inadequate response or intolerance to ursodeoxycholic acid (UDCA), the current first-line therapy.
Trial Design and Patient Population
The ELATIVE trial is a multi-center, randomized, double-blind, placebo-controlled Phase III study with an open-label long-term extension. The trial enrolled 161 patients randomized 2:1 to receive elafibranor 80mg once daily or placebo. Patients with inadequate UDCA response continued UDCA in combination with study treatment, while UDCA-intolerant patients received elafibranor or placebo alone.
PBC affects the liver's small bile ducts through autoimmune destruction, potentially leading to bile and toxin accumulation, liver scarring, and eventual liver failure if untreated. The disease significantly impacts quality of life through symptoms including fatigue and severe itching, making effective symptom management crucial alongside disease progression control.